Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
about
Constraints on the Genetic and Antigenic Variability of Measles VirusReplacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidatesA tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient miceA serum-free Vero production platform for a chimeric virus vaccine candidateA recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.Altered virulence of vaccine strains of measles virus after prolonged replication in human tissue.Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage.Progress in the development of human parainfluenza virus vaccinesThe two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatednessDeterminants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.Small Animal Models for Human Metapneumovirus: Cotton Rat is More Permissive than Hamster and Mouse.Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.Nonsegmented negative-strand viruses as vaccine vectors.Successful topical respiratory tract immunization of primates against Ebola virus.Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.Human body temperature and new approaches to constructing temperature-sensitive bacterial vaccinesThe cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young childrenCodon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vectorAnalysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage.Rational attenuation of a morbillivirus by modulating the activity of the RNA-dependent RNA polymerase.Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.Progress in respiratory virus vaccine development
P2860
Q26750558-0B24F086-B5B1-4F2F-AA13-CF6C2CD17C91Q27469676-261B914F-6463-4EB3-820C-6B30C28CBC6EQ27472824-1C76B783-D7D0-4939-8255-C70B41BA9CF8Q30462034-FD6D2491-DF0C-4A92-A86E-5FE41C25E290Q33801293-69DD1D9C-36E0-419D-8490-9D342688EAABQ33808578-26EF435F-7FE5-4495-B217-784D63E727E3Q33821235-0675D5F9-BCD0-4816-A5E0-4BA45963FB02Q33835693-1D91402B-0B0D-4F64-B1CE-65A259E4CA60Q34209872-6D6C44C2-BEE7-4867-B8A4-161ED78AE78CQ34439107-D7D8A792-E4BE-456B-97F2-4D6A0088F185Q34465213-6F0F1B03-902A-4790-A2D2-CD755FFBC34BQ34569141-B19EFD8F-51B0-4708-ABF7-36BB5405AC3AQ34717853-EC6CCFAE-27EF-4700-90F0-DDA92BF1C17BQ35139219-24E7B833-8912-4FB7-8331-F2E3D6FE1D95Q35857218-35093E82-1D84-42CF-842A-235FB0C42EEBQ36088161-0FD1E517-28DC-46A6-9371-1AAD93DFD76BQ36108268-060950DA-2375-4684-8F27-4F7F272CC468Q36190502-93BED71C-EE18-4C41-AB2F-814C2AE8FD2DQ36959922-395C856A-5107-436E-8762-BD0A7274513CQ36961947-9635D93A-14DE-4EF0-A352-DE3E2AA8712DQ37342874-403FF971-75EC-471E-8A03-7AA577F794EFQ37470206-9D885ECC-B793-44B2-AE90-B7BFE118EAA7Q39593656-99F82BB0-7577-427A-9415-D2F01F0BE205Q39601579-7C2D7584-8DE3-4CF9-B395-3E3AE57F4A2CQ39612879-56932808-2682-470B-8BDD-8A8F62ED5964Q39997643-AEC1DB94-08EC-41EB-9138-E69E1E1815FEQ56894869-F9079172-638D-4156-ADB5-43DF3670C5D2
P2860
Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Identification of mutations co ...... nza virus 3 candidate vaccine.
@ast
Identification of mutations co ...... nza virus 3 candidate vaccine.
@en
type
label
Identification of mutations co ...... nza virus 3 candidate vaccine.
@ast
Identification of mutations co ...... nza virus 3 candidate vaccine.
@en
prefLabel
Identification of mutations co ...... nza virus 3 candidate vaccine.
@ast
Identification of mutations co ...... nza virus 3 candidate vaccine.
@en
P2093
P2860
P1433
P1476
Identification of mutations co ...... enza virus 3 candidate vaccine
@en
P2093
Collins PL
Paschalis M
Skiadopoulos MH
P2860
P304
P577
1999-02-01T00:00:00Z